Regulatory Rumblings

ANA Asks CA Governor to Veto AB 1202

Posted: Sep 25, 2019 12:00am ET

Yesterday ANA, and several other groups, sent a letter to the Governor of California, Gavin Newsom, urging him to veto AB 1202.


The Time For Action Is NOW

Posted: Sep 6, 2019 11:00am ET

Today CalMatters published an op-ed by me urging the California Legislature to make changes to the CCPA that are greatly needed.


CCPA Status Report 2: CCPA Implementation Timeline Creates Severe Compliance Pressures

Posted: Sep 4, 2019 12:00am ET

Once the California legislature adjourns on September 13, 2019, the last day for Governor Newsom to sign or veto bills passed by the legislature this session is October 13, 2019.


CCPA Status Report: Legislative Finish Line in Sight

Posted: Sep 3, 2019 12:00am ET

There are only 10 days until the California Legislative session ends on September 13th.


"It Is Better To Be The Hammer Than The Anvil"

Posted: Aug 19, 2019 10:25am ET

Various governments here and abroad are enforcing highly restrictive new privacy laws and putting forward a broad array of privacy proposals.


"Seller" Beware!!!

Posted: Aug 8, 2019 12:00am ET

In my last posting, I discussed the extraordinarily broad coverage of the California Consumer Privacy Act (CCPA).


Happy New Year?

Posted: Aug 1, 2019 2:30am ET

Californians celebrate the transition from one year to the next in unique and fun ways.


ANA Joins Opposition to HHS Prescription Drug Price Disclosure Rule

Posted: Jun 14, 2019 3:45pm ET

ANA has joined with Merck, Eli Lilly, and Amgen to bring a lawsuit to enjoin a HHS rule concerning prescription drugs that would otherwise blow significant holes in advertisers First Amendment protections.


Happy Birthday GDPR

Posted: May 21, 2019 10:15am ET

This week marks the first anniversary of the European Union’s General Data Protection Regulation (GDPR). When it was launched on May 25, 2018 the GDPR was clearly the most significant privacy experiment to that point in history.


ANA Strongly Opposes New HHS Ad Disclosure Rule

Posted: May 9, 2019 11:40am ET

Yesterday, the Department of Health and Human Services (HHS) finalized a new rule which would require “direct-to-consumer television advertisements for prescription pharmaceuticals covered by Medicare or Medicaid to include the list price … if that price is equal to or greater than $35.” ANA strongly opposes this government requirement which is highly likely to be unconstitutional.